Celgene Partners with Bluebird Bio to Advance CAR T-Cell Cancer Therapies
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 8 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1919 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Celgene has partnered with Bluebird bio to discover, develop and commercialise novel disease-altering gene therapies in oncology that utilise a patient’s own genetically modified T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells selectively...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS